

Blood and Transplant

Board Meeting in Public Tuesday, 26 March 2024

Title of Report	NHSBT Board Self-Effectiveness Review Report			Agenda No.	5.4.1	
Nature of Report (tick one)			□ Official S	□ Official Sensitive		
Author(s)	Brenda Thomas, Interim Company Secretary					
Lead Executive	Helen Gillan, Director of Quality					
Non-Executive Director Sponsor (if applicable)	Peter Wyman, NHSBT Chair					
Presented for (tick all that applies)	Approv	□ Approval □ Information			☑ Discussion	
	🛛 Assura	ince	🗆 Upda	ite		
Purpose of the report and key issues						
effectiveness review to be undertaken for the year to January 2024. This questionnaire mirrored the version used in the previous year's internal self-effectiveness evaluation, except for the section relating to the committees, which was omitted since the committees' self-effectiveness have been evaluated separately. The findings from the review are presented in this report, which is based on the analysis of the completed questionnaires that were submitted.						
Previously Considered by						
This report was shared with the Chair and Director of Quality.						
Recommendation	The Board is asked to review the outcomes of its self-effectiveness review, and collectively agree what actions should be taken, including areas of prioritisation and timescales for delivery.					
Risk(s) identified (Link to Board Assurance Framework Risks)						
Linked to Regulatory Compliance risk (BAF-09).						
Strategic Objective(s) this paper relates to: [Click on all that applies]						
 Collaborate with partners Modernise our operations 		• •	vest in people and culture Sow and diversify our donor base		ation	
Appendices:	Appendix 1 – Summary of analysis by section.					